| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Multiple myeloma, the second most common hematologic malignancy, is a genetically complex and heterogeneous cancer of monoclonal plasma cells. While this plasma cell neoplasm cannot be cured and most patients relapse repeatedly, survival rates have improved with the advent of targeted treatment approaches, including new, U.S. FDA-approved immunotherapies.
Multiple myeloma and its predecessors, monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM), which are considered pre-malignant states, have complex genetic associations. Understanding the genetic complexities of a patient’s condition can clarify diagnosis, inform prognosis, and help guide physicians toward timely, appropriate treatment.
Next-generation sequencing test menu
When deemed clinically necessary, next-generation sequencing (NGS) can supplement standard-of-care morphology, phenotyping, and FISH testing to refine diagnosis.
Designed to include only relevant genes, our 26-gene MayoComplete NGS panel focuses on those genes implicated in multiple myeloma to characterize diagnosis, monitor for disease progression and transition, and clarify treatment targets. Our assay involves a pre-analytical step of cell sorting and only tests DNA from the plasma cell population, which increases testing sensitivity.
Key testing